Development Of A High Acuity, Diamond Retinal Prosthesis
Funder
National Health and Medical Research Council
Funding Amount
$1,010,214.00
Summary
Over recent years our team has developed a retinal implant to restore sight to people with certain types of blindness. With 256 independently controllable electrodes this device is among the most sophisticated in the world. We aim to conduct experiments to demonstrate that our device can provide improved better visual acuity than the world leaders with a view to developing a competitive commercial medical technology.
Harnessing Anticalin Technology As A Multi-targeted Treament Approach For Vision Loss
Funder
National Health and Medical Research Council
Funding Amount
$627,273.00
Summary
Diabetes is a leading cause of vision loss and blindness worldwide and is caused by two factors called VEGF and Ang2, which damage blood vessels. Current treatments only block VEGF and many patients do not respond and suffer irreversible damage to sight. We have used ground-breaking anticalin technology to make a new drug (PRS-AUS1) that blocks both VEGF and Ang2. Studies will be performed in animal models and move to patients where we expect improved outcomes compared to current treatments.
Electrical Stimulation Of The Brain For Restoring Vision
Funder
National Health and Medical Research Council
Funding Amount
$1,555,864.00
Summary
This project is focused on the clinical demonstration of the Monash Vision Group’s ‘Gennaris’ cortical prosthesis or bionic eye. The clinical work will demonstrate the use of the Gennaris as a viable medical device that provides useful vision to people with adult-onset profound vision loss in their everyday living environments. This will place MVG in a position to attract funding from investors or commercial partners to perform multi-site clinical trials and obtain regulatory approval.
Epilepsy affects over 65 million people worldwide and approximately 30% of sufferers do not respond to drugs. For these people, electrodes are placed in the brain to monitor brain activity and stop the initiation or progression of seizures. However, state-of-the-art devices require risky open-brain surgery. In this project, we are developing a Stentrode Neuro-Stimulator (SNS) for the treatment of drug-resistant epilepsy without the need for open-brain surgery.
Development Of A Glucose-6-phosphate Dehydrogenase/ Haemoglobin Point-of-care Test For Malaria Elimination
Funder
National Health and Medical Research Council
Funding Amount
$560,608.00
Summary
Malaria elimination requires the use of specific anti-malarial drugs that treat the dormant malaria parasites in the liver. The use of these drugs in people with a deficiency of the glucose-6-phosphate dehydrogenase (G6PD) enzyme can lead to the catastrophic destruction of red blood cells and severe anaemia. There is a need for new G6PD diagnostic tests that can be delivered in remote, resource poor settings. This project will develop a G6PD point-of-care test to fast-track malaria elimination.